Osteoclast Inhibition in Postmenopausal Breast Cancer: Is the Evidence Too Strong to Ignore?

    loading  Checking for direct PDF access through Ovid

Abstract

Bone-targeted agents should be considered for all postmenopausal women with high-risk, early-stage breast cancer. Targeting the microenvironment and normal host cells is a viable strategy for preventing cancer recurrences.

See also pages 2444-51.

Related Topics

    loading  Loading Related Articles